New drug IBI3032 tested in healthy people for first time

NCT ID NCT07120425

Recruiting now Knowledge-focused Sponsor: Fortvita Biologics (USA)Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 1 trial is testing the safety and tolerability of a single dose of IBI3032 in 32 healthy adults. Participants are randomly assigned to receive either the drug or a placebo. The study is for research only and is not meant to treat any medical condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI3032
What could go wrong: This is a very early Phase 1 safety study in only 32 healthy people. It is not designed to test whether IBI3032 works for any disease, and many early-stage drugs never advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

ICON Clinical Research
RECRUITING

Lenexa, Kansas, 66219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.